Literature DB >> 22172720

β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.

William E Damsky1, David P Curley, Manjula Santhanakrishnan, Lara E Rosenbaum, James T Platt, Bonnie E Gould Rothberg, Makoto M Taketo, David Dankort, David L Rimm, Martin McMahon, Marcus Bosenberg.   

Abstract

Malignant melanoma is characterized by frequent metastasis, however, specific changes that regulate this process have not been clearly delineated. Although it is well known that Wnt signaling is frequently dysregulated in melanoma, the functional implications of this observation are unclear. By modulating β-catenin levels in a mouse model of melanoma that is based on melanocyte-specific Pten loss and Braf(V600E) mutation, we demonstrate that β-catenin is a central mediator of melanoma metastasis to the lymph nodes and lungs. In addition to altering metastasis, β-catenin levels control tumor differentiation and regulate both MAPK/Erk and PI3K/Akt signaling. Highly metastatic tumors with β-catenin stabilization are very similar to a subset of human melanomas. Together these findings establish Wnt signaling as a metastasis regulator in melanoma.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22172720      PMCID: PMC3241928          DOI: 10.1016/j.ccr.2011.10.030

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  51 in total

1.  Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma.

Authors:  K Omholt; A Platz; U Ringborg; J Hansson
Journal:  Int J Cancer       Date:  2001-06-15       Impact factor: 7.396

2.  mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide.

Authors:  Won Jun Oh; Chang-chih Wu; Sung Jin Kim; Valeria Facchinetti; Louis-André Julien; Monica Finlan; Philippe P Roux; Bing Su; Estela Jacinto
Journal:  EMBO J       Date:  2010-11-02       Impact factor: 11.598

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.

Authors:  Rosalynn M Nazarian; Victor G Prieto; David E Elder; Lyn M Duncan
Journal:  J Cutan Pathol       Date:  2010-04       Impact factor: 1.587

5.  Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 associates with insulin receptor substrate-1 and enhances insulin actions and adipogenesis.

Authors:  Yusuke Nakatsu; Hideyuki Sakoda; Akifumi Kushiyama; Jun Zhang; Hiraku Ono; Midori Fujishiro; Takako Kikuchi; Toshiaki Fukushima; Masayasu Yoneda; Haruya Ohno; Nanao Horike; Machi Kanna; Yoshihiro Tsuchiya; Hideaki Kamata; Fusanori Nishimura; Toshiaki Isobe; Takehide Ogihara; Hideki Katagiri; Yoshitomo Oka; Shin-ichiro Takahashi; Hiroki Kurihara; Takafumi Uchida; Tomoichiro Asano
Journal:  J Biol Chem       Date:  2011-03-17       Impact factor: 5.157

6.  Loss of beta-catenin expression associated with disease progression in malignant melanoma.

Authors:  T Kageshita; C V Hamby; T Ishihara; K Matsumoto; T Saida; T Ono
Journal:  Br J Dermatol       Date:  2001-08       Impact factor: 9.302

7.  Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit.

Authors:  Mehdi Khaled; Carmit Levy; David E Fisher
Journal:  Genes Dev       Date:  2010-10-15       Impact factor: 11.361

8.  Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.

Authors:  Anouk Demunter; Louis Libbrecht; Hugo Degreef; Chris De Wolf-Peeters; Joost J van den Oord
Journal:  Mod Pathol       Date:  2002-04       Impact factor: 7.842

9.  Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development.

Authors:  V Brault; R Moore; S Kutsch; M Ishibashi; D H Rowitch; A P McMahon; L Sommer; O Boussadia; R Kemler
Journal:  Development       Date:  2001-04       Impact factor: 6.868

10.  Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.

Authors:  R Wang; L D Ferrell; S Faouzi; J J Maher; J M Bishop
Journal:  J Cell Biol       Date:  2001-05-28       Impact factor: 10.539

View more
  167 in total

1.  Beta-catenin inhibits melanocyte migration but induces melanoma metastasis.

Authors:  S J Gallagher; F Rambow; M Kumasaka; D Champeval; A Bellacosa; V Delmas; L Larue
Journal:  Oncogene       Date:  2012-06-04       Impact factor: 9.867

Review 2.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

3.  LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.

Authors:  Wenjin Liu; Kimberly B Monahan; Adam D Pfefferle; Takeshi Shimamura; Jessica Sorrentino; Keefe T Chan; David W Roadcap; David W Ollila; Nancy E Thomas; Diego H Castrillon; C Ryan Miller; Charles M Perou; Kwok-Kin Wong; James E Bear; Norman E Sharpless
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

4.  Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.

Authors:  Katie M Leick; Joel Pinczewski; Ileana S Mauldin; Samuel J Young; Donna H Deacon; Amber N Woods; Marcus W Bosenberg; Victor H Engelhard; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2019-05-27       Impact factor: 6.968

5.  Tissue inhibitor of metalloproteinase 2 inhibits activation of the β-catenin signaling in melanoma cells.

Authors:  Yuxuan Xia; Shaoping Wu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Deregulated MITF sumoylation: A route to melanoma.

Authors:  Robert Ballotti; Corine Bertolotto
Journal:  Mol Cell Oncol       Date:  2017-05-26

7.  Wnt signaling potentiates nevogenesis.

Authors:  Jeff S Pawlikowski; Tony McBryan; John van Tuyn; Mark E Drotar; Rachael N Hewitt; Andrea B Maier; Ayala King; Karen Blyth; Hong Wu; Peter D Adams
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

8.  Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Authors:  Fan Huang; Christophe Gonçalves; Margarita Bartish; Joelle Rémy-Sarrazin; Mark E Issa; Brendan Cordeiro; Qianyu Guo; Audrey Emond; Mikhael Attias; William Yang; Dany Plourde; Jie Su; Marina Godoy Gimeno; Yao Zhan; Alba Galán; Tomasz Rzymski; Milena Mazan; Magdalena Masiejczyk; Jacek Faber; Elie Khoury; Alexandre Benoit; Natascha Gagnon; David Dankort; Fabrice Journe; Ghanem E Ghanem; Connie M Krawczyk; H Uri Saragovi; Ciriaco A Piccirillo; Nahum Sonenberg; Ivan Topisirovic; Christopher E Rudd; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

Review 9.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

10.  A prognostic signature of G(2) checkpoint function in melanoma cell lines.

Authors:  Bernard Omolo; Craig Carson; Haitao Chu; Yingchun Zhou; Dennis A Simpson; Jill E Hesse; Richard S Paules; Kristine C Nyhan; Joseph G Ibrahim; William K Kaufmann
Journal:  Cell Cycle       Date:  2013-03-01       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.